June 28, 2024 AstraZeneca has set out a new ambition for Healthy Heart Africa, its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs),includingchronic kidney disease (CKD) as well as hypertension and cardiovascular disease. The expanded program will also launch in Egypt, reaching even more patients across the continent. At the 77thWorld Health Assembly (WHA) during an event co-hosted with the Ministry of Health for Uganda, AstraZeneca announced that the expanded Healthy Heart Africa program will be operational in Cte d'Ivoire, Egypt, Ethiopia, Ghana, Kenya, Nigeria, Rwanda, Senegal and Uganda by the end of 2025. Continue reading →

Dive Brief: Novo bought ocedurenone from Singapore-based KBP Biosciences, one of a string of acquisitions made as it seeks to put profits from its diabetes and obesity drugs Ozempic and Wegovy to work. When Novo announced the deal, KBP had already begun a Phase 3 trial of ocedurenone in people with chronic kidney disease and hypertension that couldnt be controlled with at least two medications Continue reading →

Local physicians with the AdventHealth Heart, Lung and Vascular Institute have performed three groundbreaking proceduresone of them was conducted at Osceolas very own Celebration Hospital. Dr. Mark Steiner conducted the first commercial renal denervation, a minimally invasive procedure that can treat high blood pressure that cant be controlled via optimal therapy, in Central Florida Continue reading →